Drug Shortage Report for BIVALIRUDIN FOR INJECTION
| Report ID | 170875 |
| Drug Identification Number | 02435268 |
| Brand name | BIVALIRUDIN FOR INJECTION |
| Common or Proper name | BIVALIRUDIN FOR INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | BIVALIRUDIN |
| Strength(s) | 250MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10mL |
| ATC code | B01AE |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-10-15 |
| Actual start date | |
| Estimated end date | 2022-12-19 |
| Actual end date | 2022-12-19 |
| Shortage status | Resolved |
| Updated date | 2023-01-02 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Bivalirudin for Injection 250 mg/vial SD Vial 10 mL effective October 15, 2022 until December 19, 2022. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2023-01-02 | French | Compare |
| v4 | 2023-01-02 | English | Compare |
| v3 | 2022-10-16 | English | Compare |
| v2 | 2022-10-02 | French | Compare |
| v1 | 2022-10-02 | English | Compare |
Showing 1 to 5 of 5